Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Aug 15.

Published in final edited form as: Clin Cancer Res. 2022 Feb 15;28(4):748–755. doi: 10.1158/1078-0432.CCR-21-3088

Table 1.

Association of MVD and MCD dichotomous groups with PFS and OS.

		Univariate Analysis		Multivariable Analysis
	N. of events/ N. of Patients	Months, Median (95% CI)	Unadjusted^* HR (95% CI)	Adjusted^* HR (95% CI)	Adjusted^* p-value
Microvascular density
OS
Low (≤208.2 mm²)	121/240	18.4 (15.9–20.0)	Ref.	Ref.	0.1407
High (>208.2 mm²)	48/120	NR (18.0-NR)	0.72 (0.51–1.00)	0.78 (0.55–1.09)
PFS
Low (≤208.2 mm²)	154/240	5.4 (3.9–5.6)	Ref.	Ref.	0.0144
High (>208.2 mm²)	66/120	7.3 (6.3–9.2)	0.66 (0.50–0.88)	0.69 (0.52–0.93)
Mast cell density
OS
Low (≤11.3 mm²)	110/216	18.4 (15.9 –19.6)	Ref.	Ref.
High (>11.3 mm²)	39/109	NR (20.4-NR)	0.66 (0.44– 0.92)	0.69 (0.48–0.99)	0.0451
PFS
Low (≤11.3 mm²)	142/216	5.5 (4.0–5.6)	Ref.	Ref.
High (>11.3 mm²)	54/109	7.5 (7.2–9.2)	0.64 (0.47–0.87)	0.66 (0.48–0.91)	0.0112

^*

Adjusted for IMDC risk group, presence of bone metastases and number of previous VEGFR TKI treatment (1 or ≥2)